Human IGFBP-6 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF876
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Neutralization, Western Blot
Cited:
Neutralization, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human IGFBP-6
Ala25-Gly240
Accession # NP_002169
Ala25-Gly240
Accession # NP_002169
Specificity
Detects human IGFBP‑6 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 30% cross‑reactivity with recombinant mouse IGFBP-6 is observed, 5% cross‑reactivity with recombinant human (rh) IGFBP-2 is observed and less than 1% cross‑reactivity with rhIGFBP-1, rhIGFBP-3, rhIGFBP-4, and rhIGFBP-5 is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IGFBP-6 Antibody
IGFBP‑6 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑6 Antibody.
Recombinant Human IGFBP-6 (Catalog # 876-B6) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-6 (0.8 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IGFBP-6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF876). The ND50 is typically 8-24 µg/mL.Applications for Human IGFBP-6 Antibody
Application
Recommended Usage
Western Blot
0.1 µg/mL
Sample: Recombinant Human IGFBP-6 (Catalog # 876-B6)
Sample: Recombinant Human IGFBP-6 (Catalog # 876-B6)
Neutralization
Measured by its ability to neutralize IGFBP‑6 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND50) is typically 8‑24 µg/mL in the presence of 0.8 µg/mL Recombinant Human IGFBP‑6 and 14 ng/mL Recombinant Human IGF‑II.
Reviewed Applications
Read 2 reviews rated 2 using AF876 in the following applications:
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IGFBP-6
Human IGFBP-6 cDNA encodes a 240 amino acid (aa) residue precursor protein with a putative 24 aa residue signal peptide that is processed to generate the 216 aa residue mature protein that is O-glycosylated. IGFBP-6 is expressed in ovarian cells, prostatic cells, and fibroblasts. IGFBP‑6 is found predominantly in CSF and serum. IGFBP-6 binds preferentially to IGF-II, exhibiting a 2-fold higher affinity for IGF-II than for IGF-I.
References
- Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
- Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.
Long Name
Insulin-like Growth Factor Binding Protein 6
Alternate Names
IGFBP6
Gene Symbol
IGFBP6
UniProt
Additional IGFBP-6 Products
Product Documents for Human IGFBP-6 Antibody
Product Specific Notices for Human IGFBP-6 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...